Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain
The oncolytic mutant vesicular stomatitis virus VSVΔ51 achieves robust efficacy in multiple extracranial tumor models. Yet for malignancies of the brain, direct intratumoral infusion of VSVΔ51 causes lethal virus-induced neuropathology. Here, we have developed a novel therapeutic regime that uses pe...
Main Authors: | Lukxmi Balathasan, Vera A. Tang, Beta Yadollahi, Jan Brun, Melanie Labelle, Charles Lefebvre, Stephanie L. Swift, David F. Stojdl |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-12-01
|
Series: | Molecular Therapy: Oncolytics |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770517300438 |
Similar Items
-
The Role of the Innate Immune System in Oncolytic Virotherapy
by: Tuan Anh Phan, et al.
Published: (2017-01-01) -
Oncolytic virotherapy
by: Daniel Cervantes-García;, et al.
Published: (2008-01-01) -
Transforming the prostatic tumor microenvironment with oncolytic virotherapy
by: Matthew J. Atherton, et al.
Published: (2018-07-01) -
Oncolytic Virotherapy in Glioma Tumors
by: Sergio Rius-Rocabert, et al.
Published: (2020-10-01) -
Delivery and Biosafety of Oncolytic Virotherapy
by: Lizhi Li, et al.
Published: (2020-04-01)